
Cryo-EM focused biotech from longtime NIH veteran secures $40M backing from Bayer in Series A
“It’s always nice to get money in the bank.”
That’s what Gandeeva Therapeutics’ founder and CEO Sriram Subramaniam said after revealing that his company landed $40 million in Series A funding. Gandeeva will use the money for its artificial intelligence-enabled platform to identify small molecules and biologics at a faster pace.
The company is on a mission to show that it can leverage cryo-EM and AI to make a meaningful impact on drug discovery, and it plans to do so with speed, using AI for experiment prediction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.